⏿ The PanNASH Initiative is an interactive web-based platform presenting global NASH statistics to inform NASH control and research.
NASH is characterized by multiple underlying genetic mutations, with no approved cure to date. Gene therapies that target those genetic mutations may play a major role in treating this disease, once delivered specifically to the hepatocytes. .....
The current clinical practice is urged to incorporate biopsy-free scoring systems that demonstrate adequate performance metrics for the accurate detection of patients with MAFLD and underlying .....
Bile acids synthesis and metabolism have been impaired in NASH patients because of liver injury, inflammation or obstruction of bile ducts. Changes in bile acids composition might contribute to NASH .....
In this video, Prof. Sven Francque (Belgium) discusses how vascular mechanisms contribute to non-alcoholic fatty liver disease (NAFLD) and how non-alcoholic steatohepatitis (NASH) contributes to cardiovascular disease (CVD). He also mentions that drugs used to prevent/treat CVD and NAFLD/NASH are safe and those that are used to prevent/treat CVD can have some benefits for NAFLD.
Prof. Onno Holleboom reviews the strong co-occurence of non-alcoholic fatty liver disease (NAFLD) and atherosclerotic cardiovascular (CVD) disease in this video along with joint pathophysiological pathways and its shared drivers. He further looks into NAFLD and its relationships and effects with atherosclerotic CVD and heart failure. For clinicians, he provides an analyses of the management and diagnosis options for advanced NAFLD.
Development and severity of NAFLD have been linked to obesity and white adipose tissue dysfunction plays a key role in this relation. Ó. Osorio-Conles et al. ....
The so far well-received new name and redefinition of fatty liver disease have generated debates. The most common argument is that .....
I. Y. CHoi et al. (Total Healthcare Centre, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea) investigated the association .....
The impact of changes in sleep duration and sleep quality over time on the risk of NAFLD is not known. In a cohort study included 86,530 Korean adults.....
In this review, C. Engelmann C and F. Tacke (Campus Virchow-Klinikum and Campus Charité Mitte, Charité-Universitätsmedizin Berlin, Germany) critically discuss the currently .....
This retrospective study aimed to evaluate a possible connection between NAFLD, colonic diverticulosis, and metabolic syndrome.For the authors,......
Prof. Maarten Tushuizen provides a comprehensive review on Non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) and why it is a multisystem disease and further goes on to evaluate their connection to type 2 diabetes mellitus (T2DM) and cardiovascular disease. He also delves into the next steps of managing and diagnosing NASH and NAFLD.